Technology
Since 2001, Immuno Research Inc. has been devoted to the research and development of a differentiated, well-tolerated class of PAMPs, the beta 1,3/1,6 glucans.
- Differentiated biological targets
- Beta 1,3-1,6 glucans are recognized by a different set of receptors expressed on a range of innate immune cells:
- Complement Receptor 3 (CR3; CD11b/CD18)
- Complement Receptor 2 (CD21)
- Dectin 1 (CLEC7A)
- Lactosylceramide
- Beta 1,3-1,6 glucans are recognized by a different set of receptors expressed on a range of innate immune cells:
- Wide therapeutic index
- Our lead beta glucan is administered systemically and has a strong safety profile in both healthy volunteers and patients
- The ability to orchestrate a coordinated immune response
- Preclinical studies have demonstrated that beta glucans directly impact the biological activity and function of both innate and adaptive immune cells including:
- Modulation of immune suppressive/immune active phenotype of macrophages and neutrophils
- Modulation/maturation of dendritic cells
- Modulation of checkpoint proteins on myeloid cells
- Modulation of CD4/CD8 T-cell proliferation and function
- Preclinical studies have demonstrated that beta glucans directly impact the biological activity and function of both innate and adaptive immune cells including:
Importantly, our research has also demonstrated that the primary, secondary and tertiary structure of beta-glucans has a marked effect on their interaction with immune targets and their subsequent activity.
Our science has been the subject of a number of peer-reviewed publications in internationally recognized journals including Nature and Blood.
